TISIDB

Summary
Symbol	JAK1
Name	Janus kinase 1
Aliases	JAK1A; JTK3; JAK1B; JAK1AB; JAK-1; Tyrosine-protein kinase JAK1
Chromosomal Location	1p32.3-p31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Endomembrane system; Peripheral membrane protein. Note=Wholly intracellular, possibly membrane associated.
Domain	PF07714 Protein tyrosine kinase
Function	Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway (PubMed:7615558). Kinase partner for the interleukin (IL)-2 receptor (PubMed:11909529).

> Gene Ontology [ TOP ]
Biological Process	GO:0001525 angiogenesis GO:0001959 regulation of cytokine-mediated signaling pathway GO:0002040 sprouting angiogenesis GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0034340 response to type I interferon GO:0034341 response to interferon-gamma GO:0038083 peptidyl-tyrosine autophosphorylation GO:0038110 interleukin-2-mediated signaling pathway GO:0045088 regulation of innate immune response GO:0045765 regulation of angiogenesis GO:0045766 positive regulation of angiogenesis GO:0046677 response to antibiotic GO:0046777 protein autophosphorylation GO:0048514 blood vessel morphogenesis GO:0060330 regulation of response to interferon-gamma GO:0060333 interferon-gamma-mediated signaling pathway GO:0060334 regulation of interferon-gamma-mediated signaling pathway GO:0060337 type I interferon signaling pathway GO:0060338 regulation of type I interferon-mediated signaling pathway GO:0060759 regulation of response to cytokine stimulus GO:0070669 response to interleukin-2 GO:0071346 cellular response to interferon-gamma GO:0071352 cellular response to interleukin-2 GO:0071357 cellular response to type I interferon GO:1901342 regulation of vasculature development GO:1903670 regulation of sprouting angiogenesis GO:1903672 positive regulation of sprouting angiogenesis GO:1904018 positive regulation of vasculature development
Molecular Function	GO:0001664 G-protein coupled receptor binding GO:0004713 protein tyrosine kinase activity GO:0004715 non-membrane spanning protein tyrosine kinase activity GO:0005085 guanyl-nucleotide exchange factor activity GO:0005088 Ras guanyl-nucleotide exchange factor activity GO:0005126 cytokine receptor binding GO:0005131 growth hormone receptor binding GO:0019902 phosphatase binding GO:0019903 protein phosphatase binding GO:0031625 ubiquitin protein ligase binding GO:0031730 CCR5 chemokine receptor binding GO:0042379 chemokine receptor binding GO:0044389 ubiquitin-like protein ligase binding GO:0048020 CCR chemokine receptor binding GO:0051427 hormone receptor binding
Cellular Component	GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0009898 cytoplasmic side of plasma membrane GO:0019897 extrinsic component of plasma membrane GO:0019898 extrinsic component of membrane GO:0030055 cell-substrate junction GO:0031234 extrinsic component of cytoplasmic side of plasma membrane GO:0098552 side of membrane GO:0098562 cytoplasmic side of membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04151 PI3K-Akt signaling pathway hsa04380 Osteoclast differentiation hsa04550 Signaling pathways regulating pluripotency of stem cells hsa04621 NOD-like receptor signaling pathway hsa04630 Jak-STAT signaling pathway
Reactome	R-HSA-170984: ARMS-mediated activation R-HSA-1169410: Antiviral mechanism by IFN-stimulated genes R-HSA-422475: Axon guidance R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-1266738: Developmental Biology R-HSA-186763: Downstream signal transduction R-HSA-2871796: FCERI mediated MAPK activation R-HSA-2454202: Fc epsilon receptor (FCERI) signaling R-HSA-170968: Frs2-mediated activation R-HSA-392451: G beta R-HSA-397795: G-protein beta R-HSA-388396: GPCR downstream signaling R-HSA-114604: GPVI-mediated activation cascade R-HSA-179812: GRB2 events in EGFR signaling R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK R-HSA-109582: Hemostasis R-HSA-2428924: IGF1R signaling cascade R-HSA-6788467: IL-6-type cytokine receptor ligand interactions R-HSA-112399: IRS-mediated signalling R-HSA-2428928: IRS-related events triggered by IGF1R R-HSA-1169408: ISG15 antiviral mechanism R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-74751: Insulin receptor signalling cascade R-HSA-913531: Interferon Signaling R-HSA-909733: Interferon alpha/beta signaling R-HSA-877300: Interferon gamma signaling R-HSA-912526: Interleukin receptor SHC signaling R-HSA-6783783: Interleukin-10 signaling R-HSA-451927: Interleukin-2 signaling R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling R-HSA-6785807: Interleukin-4 and 13 signaling R-HSA-6783589: Interleukin-6 family signaling R-HSA-1059683: Interleukin-6 signaling R-HSA-1266695: Interleukin-7 signaling R-HSA-5683057: MAPK family signaling cascades R-HSA-112411: MAPK1 (ERK2) activation R-HSA-5684996: MAPK1/MAPK3 signaling R-HSA-110056: MAPK3 (ERK1) activation R-HSA-375165: NCAM signaling for neurite out-growth R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-76002: Platelet activation, signaling and aggregation R-HSA-169893: Prolonged ERK activation events R-HSA-112409: RAF-independent MAPK1/3 activation R-HSA-5673001: RAF/MAP kinase cascade R-HSA-8853659: RET signaling R-HSA-912694: Regulation of IFNA signaling R-HSA-877312: Regulation of IFNG signaling R-HSA-180336: SHC1 events in EGFR signaling R-HSA-112412: SOS-mediated signalling R-HSA-162582: Signal Transduction R-HSA-177929: Signaling by EGFR R-HSA-372790: Signaling by GPCR R-HSA-74752: Signaling by Insulin receptor R-HSA-449147: Signaling by Interleukins R-HSA-2586552: Signaling by Leptin R-HSA-186797: Signaling by PDGF R-HSA-1433557: Signaling by SCF-KIT R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) R-HSA-194138: Signaling by VEGF R-HSA-166520: Signalling by NGF R-HSA-187687: Signalling to ERKs R-HSA-167044: Signalling to RAS R-HSA-187706: Signalling to p38 via RIT and RIN R-HSA-4420097: VEGFA-VEGFR2 Pathway R-HSA-5218921: VEGFR2 mediated cell proliferation

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04151 PI3K-Akt signaling pathway
hsa04380 Osteoclast differentiation
hsa04550 Signaling pathways regulating pluripotency of stem cells
hsa04621 NOD-like receptor signaling pathway
hsa04630 Jak-STAT signaling pathway

Reactome

R-HSA-170984: ARMS-mediated activation
R-HSA-1169410: Antiviral mechanism by IFN-stimulated genes
R-HSA-422475: Axon guidance
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-186763: Downstream signal transduction
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-392451: G beta
R-HSA-397795: G-protein beta
R-HSA-388396: GPCR downstream signaling
R-HSA-114604: GPVI-mediated activation cascade
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-109582: Hemostasis
R-HSA-2428924: IGF1R signaling cascade
R-HSA-6788467: IL-6-type cytokine receptor ligand interactions
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-1169408: ISG15 antiviral mechanism
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-913531: Interferon Signaling
R-HSA-909733: Interferon alpha/beta signaling
R-HSA-877300: Interferon gamma signaling
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-6783783: Interleukin-10 signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-6783589: Interleukin-6 family signaling
R-HSA-1059683: Interleukin-6 signaling
R-HSA-1266695: Interleukin-7 signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-112411: MAPK1 (ERK2) activation
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-110056: MAPK3 (ERK1) activation
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-169893: Prolonged ERK activation events
R-HSA-112409: RAF-independent MAPK1/3 activation
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-912694: Regulation of IFNA signaling
R-HSA-877312: Regulation of IFNG signaling
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation

Summary
Symbol	JAK1
Name	Janus kinase 1
Aliases	JAK1A; JTK3; JAK1B; JAK1AB; JAK-1; Tyrosine-protein kinase JAK1
Chromosomal Location	1p32.3-p31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between JAK1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between JAK1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
18281483	Primary Cutaneous T-Cell Non-Hodgkin Lymphoma	Inhibit immunity (T and NK cell function); immunotherapy target	They also suggest two novel therapeutic approaches to CTCL and, possibly, other CD4+ T-cell lymphomas: inhibition of the Jak1/Jak3 kinase complex and, given the known strong immunostimulatory properties of IL-21 on CD8+ T, natural killer, and B cells, application of this cytokine to boost an immune response against malignant CD4+ T cells.
28783722	Melanoma	Promote immunity (T cell function); essential for immunotherapy	For example, loss-of-function mutations in β -2-microglobulin (B2M) and Janus kinases (JAK1 and JAK2) have been reported in patients unresponsive to immunotherapies. We show that APLNR interacts with JAK1, modulating interferon-γ responses in tumours, and that its functional loss reduces the efficacy of adoptive cell transfer and checkpoint blockade immunotherapies in mouse models.
28723893	Melanoma	Promote immunity; increase the efficacy of immunotherapy	We confirmed this finding in an in vivo competitive assay that compared the relative growth of mixtures of isogenic Stat1-null or control B16 cells in animals treated with immunotherapy (Fig. 1f). In wild-type mice treated with GVAX and anti-PD-1 immunotherapy, the relative proportion of Stat1-null cells increased significantly (Fig. 1g, h; P < 0.01, Student’s t-test), suggesting that Stat1-null cells have a marked growth advantage over wild-type tumour cells when under immune attack. Similar results were obtained for Jak1-null and Ifngr1-null cells (Fig. 1h).
16474838	Uterine Corpus Leiomyosarcoma	Promote immunity (T cell function)	The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2. Tumor cells may alter the antigen presentation by HLA class I, allowing them to evade antitumor immunity. In many cases, the lack of antigen presentation can be attributed to the downregulation of genes needed for antigen processing, such as the transporters associated with antigen processing (TAP) 1, and the proteasomal component, low molecular weight proteins (LMP) 2.
27433843	Melanoma	Promote immunity	Whole-exome sequencing detected clonal selection and outgrowth of the acquired resistant tumors and, in two of the four patients, revealed resistance-associated loss-of-function mutations in the genes encoding interferon-receptor-associated Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), concurrent with deletion of the wild-type allele. JAK1 and JAK2 truncating mutations resulted in a lack of response to interferon gamma, including insensitivity to its antiproliferative effects on cancer cells.
28539123	Colorectal Carcinoma	Essential for immunotherapy	JAK1 loss-of-function mutations were validated with an overall frequency of 20% in Norwegian and British patients, and mutated tumors had up-regulation of transcriptional signatures associated with resistance to anti-PD-1 treatment.
29090321	Hepatocellular Carcinoma	Inhibit immunity (T cell function)	In the present study, we asked whether TNF-α can promote the expression of B7-H1 induced by IFN-γ in HCC cells. We found that JAK/STAT1/IRF1 was the primary pathway responsible for induction of B7-H1 expression by IFN-γ in human HCC cell lines. TNF-α and IFN-γ synergistically induced the expression of B7-H1 in the HCC cells. Moreover, the mechanism of the synergy was that TNF-α enhanced IFN-γ signaling by upregulating the expression of IFN-γ receptors.
29034543	Gastric Carcinoma	Inhibit immunity (T cell function)	PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Our in?vitro findings showed that interferon gamma upregulated programmed death ligand-1 expression on solid tumor cells through the JAK-signal transducer and activator of transcription pathway, and impaired the cytotoxicity of tumor antigen-specific CTL against tumor cells.
28008925	Bladder Carcinoma	Promote immunity	Cells from this patient exhibit reduced JAK1 and STAT phosphorylation following cytokine stimulations, reduced induction of expression of interferon-regulated genes and dysregulated cytokine production; which are indicative of signalling defects in multiple immune response pathways including Interferon-γ production.
29872580	Melanoma	Promote immunity; Essential for immunotherapy	Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. In this study, we dissected the specific roles of individual JAK/STAT pathway members on the IFN-γ response, and identified JAK1 as the primary mediator of JAK/STAT signaling associated with IFN-γ-induced expression of antigen-presenting molecules MHC-I and MHC-II, as well as PD-L1 and the cytostatic response to IFN-γ.
23386060	Breast Carcinoma; Cervical Carcinoma	Promote immunity	we show that hCAF1/CNOT7 regulates class I and II IFN pathways at different crucial steps.Since abnormal and unbalanced JAK/STAT activation is associated with immune disorders and cancer, hCAF1 could play a major role in innate immunity and oncogenesis, contributing to tumour escape

Summary
Symbol	JAK1
Name	Janus kinase 1
Aliases	JAK1A; JTK3; JAK1B; JAK1AB; JAK-1; Tyrosine-protein kinase JAK1
Chromosomal Location	1p32.3-p31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of JAK1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: 9.69; FDR: 0.000150	Sensitive to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: 2.50; FDR: 0.000381	Sensitive to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.71	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	STARS Score: 7.35; FDR: 0.000	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX	STARS Score: 6.12; FDR: 0.000	Sensitive to T cell-mediated killing
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	JAK1
Name	Janus kinase 1
Aliases	JAK1A; JTK3; JAK1B; JAK1AB; JAK-1; Tyrosine-protein kinase JAK1
Chromosomal Location	1p32.3-p31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of JAK1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.124	0.546
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.026	0.991
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.229	0.886
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.223	0.536
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.071	0.977
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.417	0.896
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.211	0.626
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.184	0.93
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.213	0.928
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.925	0.603
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.393	0.608
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.155	0.00333

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of JAK1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	4.1	-0.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.4	0.3	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	7.7	-7.7	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	100	-100	0.143
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	JAK1
Name	Janus kinase 1
Aliases	JAK1A; JTK3; JAK1B; JAK1AB; JAK-1; Tyrosine-protein kinase JAK1
Chromosomal Location	1p32.3-p31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of JAK1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	JAK1
Name	Janus kinase 1
Aliases	JAK1A; JTK3; JAK1B; JAK1AB; JAK-1; Tyrosine-protein kinase JAK1
Chromosomal Location	1p32.3-p31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of JAK1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by JAK1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	JAK1
Name	Janus kinase 1
Aliases	JAK1A; JTK3; JAK1B; JAK1AB; JAK-1; Tyrosine-protein kinase JAK1
Chromosomal Location	1p32.3-p31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of JAK1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	JAK1
Name	Janus kinase 1
Aliases	JAK1A; JTK3; JAK1B; JAK1AB; JAK-1; Tyrosine-protein kinase JAK1
Chromosomal Location	1p32.3-p31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of JAK1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	JAK1
Name	Janus kinase 1
Aliases	JAK1A; JTK3; JAK1B; JAK1AB; JAK-1; Tyrosine-protein kinase JAK1
Chromosomal Location	1p32.3-p31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between JAK1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	JAK1
Name	Janus kinase 1
Aliases	JAK1A; JTK3; JAK1B; JAK1AB; JAK-1; Tyrosine-protein kinase JAK1
Chromosomal Location	1p32.3-p31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting JAK1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting JAK1.

ID	Name	Drug Type	Targets	#Targets
DB02375	Myricetin	Small Molecule	JAK1, PIK3CG	2
DB04716	2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE	Small Molecule	DAPK3, JAK1, JAK2, JAK3, TYK2	5
DB08877	Ruxolitinib	Small Molecule	JAK1, JAK2	2
DB08895	Tofacitinib	Small Molecule	JAK1, JAK2, JAK3, TYK2	4
DB11817	Baricitinib	Small Molecule	JAK1, JAK2, JAK3, PTK2B	4

Browse JAK1